- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A third‑party promotional email for Nustendi quoted a “38% LDL‑C reduction (placebo‑corrected)”. The PMCPA ruled the layout implied this was vs ezetimibe…
PMCPA ruled GSK’s “Trevor trusts Trelegy” claim on an HCP website was ambiguous, misleading and unsubstantiated (Clauses 6.1, 6.2, 5.1). No breach…
Complaint alleged Besins Hormone Academy webpages were disguised promotion. Panel found it was clearly a Besins HCP site with PI link and…
CSL Vifor voluntarily admitted breaches after a global team sent a UK HCP an uncertified email invite/flyer for an overseas CKD-aP meeting…
PMCPA ruled AstraZeneca breached Clause 5.5 after a contracted HCP tweeted #speakupforCOPD without declaring their association. Website disclosure was deemed sufficiently prominent;…
PMCPA found Moderna responsible for a senior employee’s policy articles and X reposts. Missing disclosure breached Clause 5.5 and high standards (5.1).…
Complaint alleged Evra ad and linked ‘Benefits’/‘Safety & tolerability’ pages omitted full indication and key risks/contraindications. Panel found no breach of Clauses…
Complaint alleged a COPD therapy review service was misclassified as Joint Working and that software, patient leaflets and consultation summaries weren’t certified.…
A pharmacist complained a launch letter promoted off-label use of Melatonin 1mg/ml Oral Solution. The Panel ruled the letter promoted off-label use,…
A primary care trust chief pharmacist questioned whether a Champix ad in the Health Service Journal could be seen by non-health professionals.…
Roche was ruled in breach after Xenical was effectively supplied via a non-health professional at a private clinic and a proposed £55,000…
A freelance medical writer challenged Ferinject materials used at a renal meeting. The Panel ruled claims about dosing and infusion-time comparisons misleading,…
GSK challenged Pfizer’s Champix detail aid on efficacy comparisons vs NRT, NNT and cost-effectiveness claims, and safety/prescribing information. The Panel ruled no…
Roche challenged two GSK corporate press releases about lapatinib (Tykerb/Tyverb). The Panel found one release misleading on adverse event/risk-benefit balance, but rejected…
Cephalon challenged ProStrakan leavepieces claiming Abstral provided rapid relief from 10 minutes. The Panel found the claim inconsistent with the Abstral SPC,…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.